Company: CYTK
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013167
Chunk: 79

Company: CYTOKINETICS INC
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 79
---
d” with the Commission and is not to be incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. Our committee has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with management and, based on such review and discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this Proxy Statement and incorporated into the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Members of the Compensation and Talent Committee Nancy J. Wysenski, Chair Edward M. Kaye Wendell Wierenga Compensation Committee Interlocks and Insider Participation During 2024, our Compensation Committee consisted (at various times) of Ms. Wysenski, Dr. Kaye, Dr. Wierenga, Santo J. Costa (prior to his retirement in November 2024), and Sandford D. Smith (prior to the expiration of his term in May 2024), and no current or former member of the Compensation Committee or named executive officer served as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our Board of Directors or Compensation Committee. The current and former members of the Compensation Committee were not officers or employees of the Company while a member of the Compensation Committee at any time during the calendar year 2024. Risk Analysis of the Compensation Programs The Compensation Committee has reviewed our compensation policies as generally applicable to our employees and believes that our policies do not encourage excessive and unnecessary risk-taking and that the level of risk that they do encourage is not reasonably likely to have a material adverse effect on us. The design of our compensation policies and programs is intended to encourage our employees to remain focused on both our short- and long-term goals. For example, while our cash bonus plans measure corporate and individual performance on an annual basis, the stock options typically vest over a number of years, which the Compensation Committee believes encourages employees to focus on sustained stock price appreciation, thus limiting the potential value of excessive risk-taking.

| 54 |     | Cytokinetics, Inc.|2025 Proxy Statement |

TABLE OF CONTENTS EXECUTIVE COMPENSATION

Executive Summary Compensation Table for 2024 The following table summarizes the total compensation earned by or paid to each named executive officer for the fiscal years ended December 31